| Literature DB >> 25692147 |
Darioush Iranpour1, Mojtaba Hassanpour2, Hossein Ansari3, Saeed Tajbakhsh4, Gholamreza Khamisipour5, Akram Najafi6.
Abstract
OBJECTIVES: In 2013, Clermont classified E. coli strains into eight phylogenetic groups using a new quadruplex PCR method. The aims of this study were to identify the phylogenetic groups of E. coli based on this method and to assess their antibiotic resistance patterns in Bushehr, Iran.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25692147 PMCID: PMC4322292 DOI: 10.1155/2015/846219
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Primer sequences used in the extended quadruplex phylotyping method [6].
| PCR reaction | Primer ID | Target | Primer sequence | PCR product (bp) |
|---|---|---|---|---|
| Quadruplex | chuA.1b |
| 5-ATGGTACCGGACGAACCAAC-3 | 288 |
| chuA.2 | 5-TGCCGCCAGTACCAAAGACA-3 | |||
| yjaA.1b |
| 5-CAAACGTGAAGTGTCAGGAG-3 | 211 | |
| yjaA.2b | 5-AATGCGTTCCTCAACCTGTG-3 | |||
| TspE4C2.1b |
| 5-CACTATTCGTAAGGTCATCC-3 | 152 | |
| TspE4C2.2b | 5-AGTTTATCGCTGCGGGTCGC-3 | |||
| AceK.f |
| 5-AACGCTATTCGCCAGCTTGC-3 | 400 | |
| ArpA1.r | 5-TCTCCCCATACCGTACGCTA-3 | |||
|
| ||||
| Group E | ArpAgpE.f |
| 5-GATTCCATCTTGTCAAAATATGCC-3 | 301 |
| ArpAgpE.r | 5-GAAAAGAAAAAGAATTCCCAAGAG-3 | |||
|
| ||||
| Group C | trpAgpC.1 |
| 5-AGTTTTATGCCCAGTGCGAG-3 | 219 |
| trpAgpC.2 | 5-TCTGCGCCGGTCACGCCC-3 | |||
|
| ||||
| Internal control | trpBA.f |
| 5-CGGCGATAAAGACATCTTCAC-3 | 489 |
| trpBA.r | 5-GCAACGCGGCCTGGCGGAAG-3 | |||
Figure 1Quadruplex PCR profiles of new Clermont phylotyping method. Lane 1, unknown (+ − + +); lane 2, unknown (+ + + +); lane 3, group B2 (− + + +); lane 4, group B2 (− + + −); lane 5, group F (− + − −); lane 6, group D (+ + − +); lane 7, group D (+ + − −); lane 8, group E (+ + + −); lane 9, group E (+ + − +); lane 10, group E (+ + − −); lane 11, group C (+ − + −); lane 12, group B1 (+ − − +); lane 13, group A (+ − + −). M: molecular weight marker (50 bp, Fermentas).
Prevalence of resistance among various phylogenetic groups of E. coli isolates.
| Antibiotics by class | Antibiotic | Phylogenetic group | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| B1 | B2 | F | U | D | E | Clade I | C | A | |||
| Aminoglycosides | Gentamycin | — | 15 (10.7) | 3 (2.1) | 5 (3.6) | 1 (0.7) | 3 (2.1) | 1 (0.7) | 1 (0.7) | — | 29 (20.7) |
| Amikacin | — | 5 (3.6) | — | 1 (0.7) | 1 (0.7) | — | — | — | — | 7 (5) | |
|
| |||||||||||
| Beta-lactams | Amoxicillin | 4 (2.9) | 50 (35.7) | 3 (2.1) | 31 (22.1) | 2 (1.4) | 9 (6.4) | 9 (6.4) | 6 (4.3) | 1 (0.7) | 115 (82.1) |
| Ampicillin | 4 (2.9) | 49 (35) | 3 (2.1) | 30 (21.4) | 1 (0.7) | 9 (6.4) | 9 (6.4) | 6 (4.3) | 1 (0.7) | 112 (80) | |
| Cephalothin | — | 32 (22.9) | 3 (2.1) | 15 (10.7) | — | 5 (3.6) | 3 (2.1) | 4 (2.9) | 1 (0.7) | 63 (45) | |
| Ceftriaxone | — | 29 (20.7) | 3 (2.1) | 15 (10.7) | — | 5 (3.6) | 3 (2.1) | 4 (2.9) | 1 (0.7) | 60 (42.9) | |
| Cefotaxime | — | 29 (20.7) | 3 (2.1) | 14 (10) | — | 5 (3.6) | 3 (2.1) | 3 (2.1) | 1 (0.7) | 58 (41.4) | |
| Ceftazidime | — | 22 (15.7) | 2 (1.4) | 10 (7.1) | — | 4 (2.9) | 3 (2.1) | 2 (1.4) | 1 (0.7) | 44 (31.4) | |
| Ceftizoxime | — | 14 (10) | 1 (0.7) | 3 (2.1) | — | 2 (1.4) | 3 (2.1) | 1 (0.7) | 1 (0.7) | 25 (17.9) | |
|
| |||||||||||
| Sulfonamides | Trimethoprim-sulfamethoxazole | 1 (0.7) | 32 (22.9) | 2 (1.4) | 25 (17.9) | 2 (1.4) | 7 (5) | 6 (4.3) | 5 (3.6) | 1 (0.7) | 81 (57.9) |
|
| |||||||||||
| Quinolones | Nalidixic acid | 1 (0.7) | 30 (21.4) | 3 (2.1) | 16 (11.4) | — | 5 (3.6) | 5 (3.6) | 2 (1.4) | 1 (0.7) | 63 (45) |
| Levofloxacin | 1 (0.7) | 26 (18.6) | 3 (2.1) | 11 (7.9) | — | 5 (3.6) | 1 (0.7) | 2 (1.4) | 1 (0.7) | 50 (35.7) | |
| Norfloxacin | 1 (0.7) | 26 (18.6) | 3 (2.1) | 10 (7.1) | — | 5 (3.6) | — | 2 (1.4) | 1 (0.7) | 48 (34.3) | |
| Ofloxacin | 1 (0.7) | 25 (17.9) | 3 (2.1) | 10 (7.1) | — | 5 (3.6) | 1 (0.7) | 2 (1.4) | 1 (0.7) | 48 (34.3) | |
| Ciprofloxacin | 1 (0.7) | 26 (18.6) | 3 (2.1) | 9 (6.4) | — | 5 (3.6) | 1 (0.7) | 2 (1.4) | 1 (0.7) | 48 (34.3) | |
|
| |||||||||||
| Carbapenem | Imipenem | — | 23 (16.4) | 3 (2.1) | 7 (5) | — | 4 (2.9) | 1 (0.7) | 2 (1.4) | 1 (0.7) | 41 (29.3) |
| Meropenem | — | — | — | — | — | — | 1 (0.7) | — | — | 1 (0.7) | |
|
| |||||||||||
| Nitrofurans | Nitrofurantoin | — | 1 (0.7) | — | — | — | — | 1 (0.7) | — | — | 2 (1.4) |
*Numbers in parenthesis are percentages.